BCAB实时信号 | 通过Getagraph.com最大化利润

出售 137188 min ago

@ $2.35

发出时间: 14 Feb 2024 @ 22:33

回报率: 20.43%

上一信号: Feb 12 - 23:14

上一信号: 购买

回报率: -12.31 %

Live Chart Being Loaded With Signals

Commentary (18 May 2024 @ 04:00):

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer...

Stats
今日成交量	570 285
平均成交量	642 980
市值	136.17M
EPS	$0 ( 2024-05-14 )
下一个收益日期	( $-0.490 ) 2024-08-06
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.140
ATR14	$0.00800 (0.28%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-30	Sievers Eric	Sell	572	Common Stock
2024-04-30	Smith Scott Andrew	Sell	2 181	Common Stock
2024-03-31	Smith Scott Andrew	Sell	2 181	Common Stock
2024-03-31	Sievers Eric	Sell	572	Common Stock
2024-02-29	Smith Scott Andrew	Sell	2 181	Common Stock

INSIDER POWER
93.68
Last 100 transactions
Buy: 3 003 180 \| Sell: 89 297

音量相关性

長: -0.09 (neutral)

短: 0.81 (strong)

Signal:(37.396) Same movement expected

BioAtla, Inc. 相关性

10 最正相关

10 最负相关

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

BioAtla, Inc. 相关性 - 货币/商品

-0.06
( neutral )

-0.11
( neutral )

0.00
( neutral )

0.24
( neutral )

0.00
( neutral )

0.38
( neutral )

BioAtla, Inc. 财务报表

Annual	2023
营收:	$0
毛利润:	$-1.22M (0.00 %)
EPS:	$-2.58

FY	2023
营收:	$0
毛利润:	$-1.22M (0.00 %)
EPS:	$-2.58

FY	2022
营收:	$0
毛利润:	$-1.20M (0.00 %)
EPS:	$-2.70

FY	2021
营收:	$250 000
毛利润:	$250 000 (100.00 %)
EPS:	$0

Financial Reports:

No articles found.

BioAtla, Inc. Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

BioAtla, Inc.

BioAtla, Inc., a clinical stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its lead product candidate is BA3011, a conditionally active biologic (CAB) antibody-drug conjugate (ADC) for soft tissue and bone sarcoma tumors, non-small cell lung cancer (NSCLC), and ovarian cancer. It also develops BA3021, a CAB ADC for multiple solid tumor types, including NSCLC, melanoma, and ovarian cancer; and BA3071, which is a CAB anti-cytotoxic T-lymphocyte-associated antigen 4 antibody for renal cell carcinoma, NSCLC, small cell lung cancer, hepatocellular carcinoma, melanoma, bladder cancer, gastric cancer, and cervical cancer. BioAtla, Inc. was founded in 2007 and is based in San Diego, California.